Sign in

You're signed outSign in or to get full access.

Matthew Botein

Chair of the Board at Bowhead Specialty Holdings
Board

About Matthew Botein

Matthew B. Botein, 51, is Chairperson of Bowhead Specialty Holdings Inc.’s board since May 2024. He is co‑founder and Managing Partner of Gallatin Point (since 2017), and previously served as co‑head and CIO of BlackRock Alternative Investors (2009–2017; advisor 2017–2020). He holds a B.A. magna cum laude from Harvard College and an MBA with high distinction from Harvard Business School (Baker and Loeb scholarships). He is a GPC Fund nominee to the BOW board; the proxy does not list him among directors affirmatively determined as “independent” under NYSE standards .

Past Roles

OrganizationRoleTenureCommittees/Impact
Gallatin PointCo‑Founder; Managing Partner2017–present Private investing leadership
BlackRock Alternative InvestorsCo‑Head; CIO; Advisor2009–2017; advisor 2017–2020 Led alternatives investing
Highfields Capital ManagementManaging Director; Management Committee memberNot disclosed Investment leadership
The Blackstone GroupPrivate equity departmentNot disclosed PE investing
Lazard Frères & Co. LLCPrivate equity departmentNot disclosed PE investing

External Roles

OrganizationRoleTenureCommittees/Impact
James River Group Holdings, Ltd. (Nasdaq: JRVR)DirectorCurrent Not disclosed
IDB Bank New YorkDirectorCurrent Not disclosed
Tower Hill Risk Management, LLCDirectorCurrent Not disclosed
Trusted Resource Underwriters (TRU)DirectorCurrent Interlocks with BOW insiders: Sills (director) and Fondriest (chair)
Insurance Supermarket, Inc.DirectorCurrent Not disclosed
Fortuna Holdings Ltd.DirectorCurrent Not disclosed
Northeast Bancorp (Nasdaq: NBN)DirectorCurrent Not disclosed
PennyMac Financial Services (NYSE: PFSI)DirectorPrior Not disclosed
Aspen Insurance Holdings (NYSE: AHL)DirectorPrior Not disclosed
CoreLogic Inc. (NYSE: CLGX)DirectorPrior Not disclosed
First American Corporation (NYSE: FAF)DirectorPrior Not disclosed
PennyMac Mortgage Investment Trust (NYSE: PMT)DirectorPrior Not disclosed
Beth Israel Lahey (formerly CareGroup/CJP)Board of ManagersCurrent Not disclosed

Board Governance

  • Board leadership: roles of Chair and CEO are separated; Botein serves as Chair, CEO is Stephen Sills .
  • Independence: the board ceased “controlled company” status on Oct 25, 2024 and is phasing in heightened NYSE independence requirements; directors affirmatively deemed independent are Tom Baker, Angela Brock‑Kyle, David Foy, and Ava Schnidman (Botein not among them) .
  • Attendance: board held two meetings in FY2024; each incumbent director attended at least 75% of meetings of the board and committees on which they served .
  • Committees (FY2024 activity: Audit 2 meetings; CNCG 1 meeting) .
CommitteeMembershipRole
Compensation, Nominating & Corporate Governance (CNCG)Matthew Botein; David Foy; Tom Baker; Troy Van Beek; Dr. Ava Schnidman Botein – Chair
Audit CommitteeDavid Foy (Chair); Tom Baker; Angela Brock‑Kyle Not a member

Governance signal: A sponsor‑nominated Chair (GPC Fund) leading the CNCG Committee while independence is being phased in elevates perceived conflict risk around compensation and nominations until full NYSE compliance is achieved .

Fixed Compensation

Component2024 AmountNotes
Annual Director Retainer (cash)$0 NED policy allows $80k cash + $80k RSUs or $160k RSUs; nominees of AFMIC and GPC Fund are not eligible
RSU Grant (director equity)$0 Not eligible as GPC Fund nominee; must hold if granted
Committee Chair Fee$0 Only Audit Chair receives $50k retainer; Botein chairs CNCG (no disclosed fee)
Meeting Fees$0 Not disclosed under policy; none shown for Botein
Total 2024 Director Comp$0 As reported

Performance Compensation

MetricApplies to Director Compensation?Details
Performance‑based equity (PSUs)No NED policy provides RSUs only; Botein not eligible as GPC Fund nominee
Stock optionsNo Company does not grant stock options at this time (policy applies to employees; no director options disclosed)

Executive PSU program exists (CEO PSUs with stock price CAGR hurdles: 15% threshold, 20% target, 25% max), but no performance metrics are tied to director compensation; Botein receives no director equity .

Other Directorships & Interlocks

EntityRelationship to BOWInterlock/Conflict Considerations
Trusted Resource Underwriters (TRU)External board for Botein Interlocks: Sills sits on TRU board; Fondriest chairs TRU board
GPC Fund (Gallatin Point)33.6% holder in BOW; nominee rights; nominated Botein and Cohen Board Nominee Agreement gives seat rights; Chair is GPC nominee
AFMIC (American Family Mutual Insurance Company, S.I.)14.4% holder; two BOW board nominees; extensive MGA/quota‑share agreements Related‑party exposure via reinsurance/MGA; AFMIC holds warrant; board nomination rights

Expertise & Qualifications

  • Deep alternatives and private equity investing experience (BlackRock Alternative Investors, Highfields, Blackstone, Lazard), and current managing partner of Gallatin Point .
  • Multiple current public company boards (JRVR, NBN), plus financial services and insurance boards (IDB Bank, Tower Hill, TRU), reinforcing sector knowledge relevant to BOW’s specialty P&C business .
  • Harvard College (BA magna cum laude) and Harvard Business School (MBA with high distinction; Baker and Loeb scholarships) .

Equity Ownership

HolderShares Beneficially Owned% of Outstanding
Matthew Botein (individual)0<1% (asterisk)
GPC Partners Investments (SPV III) LP (“GPC Fund”)10,968,44533.6%

Alignment signal: Botein has no disclosed personal BOW share ownership or director equity; alignment is via sponsor GPC Fund’s 33.6% stake and board rights rather than direct individual holdings .

Governance Assessment

  • Board leadership and independence: Separation of Chair/CEO is positive; however Botein (GPC nominee) is not among directors affirmatively determined as “independent,” and he chairs the CNCG Committee while the Company phases in NYSE independence—potential conflict until full compliance is completed. RED FLAG: Sponsor‑nominated chair leading compensation and nominations during phase‑in .
  • Compensation alignment: Botein receives no director cash or equity due to nominee status; this avoids pay conflicts but limits direct “skin‑in‑the‑game” alignment at the individual level. Neutral/Negative signal: no personal ownership; alignment rests at sponsor level .
  • Attendance/engagement: All incumbents met at least 75% attendance; board met twice; CNCG met once; Audit met twice—adequate but limited frequency given transformation and related‑party exposures .
  • Policies: Strong prohibitions on hedging/pledging and presence of an SEC/NYSE‑compliant clawback policy support investor protection .
  • Related‑party exposure: Significant ongoing arrangements with AFMIC (quota‑share, MGA, warrant; nomination rights) and sponsor governance agreements (GPC Board Nominee Agreement). RED FLAG: Concentrated shareholder influence and contractual rights increasing risk of conflicts; mitigated by Audit Committee oversight of related‑party transactions .
  • Section 16 compliance: No delinquency noted for Botein; Company disclosed minor filing corrections for other insiders in 2024–2025 .

Overall: Governance quality exhibits standard structures (separate Chair/CEO, formal policies) but investor confidence may be tempered by sponsor and strategic partner control dynamics—especially the CNCG chair role held by a non‑independent, sponsor‑nominated director during the independence phase‑in and material related‑party arrangements requiring strong, ongoing oversight .